Bioavailability assessment of simvastatin loaded solid lipid nanoparticles after oral administration

Asian Journal of Pharmaceutical Sciences

Volumn 6, Issue 6, 2011, Pages 251-258

  Gambhire, Makarand ^a   Bhalekar, Mangesh ^b   Shrivastava, Birendra ^a  

^a JAIPUR NATIONAL UNIVERSITY   (India)

^b AISSMS COLLEGE OF PHARMACY   (India)

Author keywords

Bioavailability; First pass metabolism; LC MS MS; Simvastatin hydroxy acid; Ultrasonication

Indexed keywords

HYDROXYACID; SIMVASTATIN; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; RAT; SLOW DRUG RELEASE; SUSPENSION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRASOUND; X RAY DIFFRACTION;

EID: 84857218685     PISSN: 18180876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Simvastatin. Martindale, the complete drug reference. In: Sweetman SC, ed. Pharmaceutical press: London. 34th edition, 2005, 997-1000.
2. Driscoll MC. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci. 2002, 15: 405-415.
3. Porter CJH, Charman WN. Intestinal lymphatic drug uptake: an update. Adv Drug Deliv Rev. 2001, 50: 61-80.
4. Charman WN, Porter CJH. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv Drug Deliv Rev. 1996, 19: 149-169.
5. Khoo SM, Humberstone AJ, Porter CJH, et al. Formulation design and bioavailability assessment of lipidic selfemulsifying formulations of halofantrine. Int J Pharm. 1998, 167: 155-164.
6. Hauss DJ, Fogal SE, Ficorilli JV, et al. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water soluble LTB4 inhibitor. J Pharm Sci. 1998, 87: 164-169.
7. Delie F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv Drug Deliv Rev. 1998, 34: 221-233.
8. Bargoni A, Cavalli R, Caputo O, et al. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res. 1998, 15:745-750.
9. Eldridge JH, Hammond CJ, Meulbrock JA, et al. Controlled vaccine release in the gut-associated lymphoid tissue, I: orally administered biodegradable microspheres target the Peyer's patches. J Control Release. 1990, 11: 205-214.
10. Pappo J, Ermak TM, Steger HJ. Monoclonal antibody directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells. Immunology. 1991, 73:277-280.
11. Jepson MA, Simmons NL, O'Hagan DT, et al. Comparison of poly (D,L-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. J Drug Target. 1993, 1:245-249.
12. Mehnert W, Mäder K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev. 2001, 47: 165- 196.
13. Müller RH, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm. 1995, 41: 62-69.
14. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000, 50: 161-177.
15. Souto EB, Müller RH. Lipid nanoparticles (SLN and NLC) for drug delivery. In: Domb A, Tabata Y, Ravi Kumar MNV, Farber, S, ed. Nanoparticles for Pharmaceutical Applications. American Scientific Publishers: California, USA. 2006, 103-122.
16. Müller RH, Lippacher A, Gohla S. Solid Lipid Nanoparticles (SLN) as Carrier System for the Controlled Release of Drugs. In: Wise D, ed. Handbook of Pharmaceutical Controlled Release Technology. Marcel Dekker, Eastern Hemisphere Distribution: M.A. 2000, 377-391.
17. Souto EB, Müller RH. Lipid nanoparticles (solid lipid nanoparticles and nanostructured lipid carriers) for cosmetic, dermal and transdermal applications. In: Thassu D, Deleers M, Pathak Y, ed. Nanoparticulate Drug Delivery Systems: Recent Trends and Emerging Technologies. CRC Press. 2007: 213-233.
18. Müller RH, Mehnert W, Souto EB. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for dermal delivery. In: Bronaugh RL, Maibach HI, ed. Percutaneous absorption: drugs, cosmetics, mechanisms, methods (drugs and the pharmaceutical sciences). Marcel Dekker: New York, Basel, Hong-Kong. 2005: 719-738.
19. Zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm. 1998, 45: 149-155.
20. Cavalli R, Bargoni A, Podio V, et al. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci. 2003, 92: 1085-1090.
21. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release. 2005, 107: 215-228.
22. Gambhire MS, Bhalekar MR, Gambhire VM. Simvastatin loaded solid lipid nanoparticles: formulation optimization using box behnken design, characterization and in vitro evaluation. Curr Pharma Res. 2011, 1: 157-164.
23. Fang JU, Fang CL, Liu CH, et al. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008, 70: 633-640.
24. Shah KA, Date AA, Joshi MD, et al. Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery. Int J Pharm. 2007, 345: 163-171.
25. Renner F, Samuelson A, Rogers M, et al. Effect of saturated and unsaturated lipid on the composition of mesenteric triglyceride-rich lipoproteins in the rat. J Lipid Res. 1986, 27: 72-81
26. Kuo YC, Su FL. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm. 2007, 340: 143-152.
27. Norris DA, Puri N, Sinko PJ. The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev. 1998, 34: 135-154.
28. Andrianov AK, Payne LG. Polymeric carriers for oral uptake of microparticulates. Adv Drug Deliv Rev. 1998, 34: 155-170.
29. Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001, 50: 3-20.
30. Florence AT, Hillery AM, Hussain N, et al. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Release. 1995, 36: 39-46.